Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: Case report and review

American Journal of Medicine

Volumn 102, Issue 1, 1997, Pages 111-112

  Perez, Carlos M ^a   Kubak, Bernard M ^a   Cryer, Henry G ^a   Salehmugodam, Saleh ^a   Vespa, Paul ^a   Farmer, Douglas ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFTRIAXONE; CLINDAMYCIN; FLUCLOXACILLIN; GENTAMICIN; IMMUNOGLOBULIN; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; STREPTOCOCCUS PYOGENES; TOXIC SHOCK SYNDROME;

EID: 0031048103     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00304-X     Document Type: Article

References (15)

1. Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriological observations of a toxic shock-like syndrome due to Streptococcus pyogenes. NEJM. 1987;317:146-149.
2. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. NEJM. 1989;321:1-7.
3. Fast DJ, Schlievert PM, Nelson RD. Toxic shock syndrome-associated Staphylococcal and Streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect Immunol. 1989;57:291-294.
4. Hackett SP, Stevens DL. Superantigens associated with Staphylococcal and Streptococcal toxic shock are potent inducers of tumor necrosis factor-B synthesis. J Infect Dis. 1993;168:232-235.
5. Braun MA, Gerlach D, Hartwig UF, et al. Stimulation of human T cells by streptococcal "superantigen" erytthrogenic toxins (scarlet fever toxins). J Immunol. 1993;150:2457-2466.
6. Tracey KJ, Cerami A. Tumor necrosis factor: an updated review of its biology. Crit Care Med. 1993;21:S415-S422.
7. Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA. 1992;267:3315-3316.
8. Yong JM. Necrotising fasciitis. Lancet. 1994;343:1427.
9. Lamothe F, D'Amico P, Ghosn P, et al. Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal infections: case report and review. Clin Infect Dis. 1995;21:1469-1470.
10. The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA. 1993;269:390-391.
11. Zumla A. Superantigens, T cells, and microbes. Clin Infect Dis. 1992;15:313-320.
12. Bohach GA, Hovde CJ, Handley JP, Schlievert PM. Cross-neutralization of staphylococcal and streptococcal pyrogenic toxins by monoclonal and polyclonal antibodies. Infect Immun. 1988;56:400-404.
13. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest. 1993;91:602-607.
14. Pinsky MR, Vincent JL, Deviere J, et al. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest. 1993;103:565-575.
15. Nadal D, Lauener RP, Braegger CP, et al. T cell activation and cytokine release in streptococcal toxic shock-like syndrome. J Pediatr. 1993;122:727-729.